Movie

Dr. No

1962

Insufficient evidence

We did not find enough credible, independent evidence to publish a numeric cash-grab score. Unrated is more honest than a guess.

What counts as a cash grab?

Commercial extraction prioritized over meaningful consumer or creative value. Profit, popularity, adaptations, sequels, remakes, high budgets, and normal marketing do not count by themselves.

Why?

Dr. No (1962) was the first Eon Productions James Bond film and contemporary production histories show it was a modestly budgeted but carefully produced adaptation of Ian Fleming, introducing much of the cinematic Bond canon rather than being a low-effort reuse. Documentation names Ken Adam art direction, Monty Norman/John Barry music, and deliberate financing and distribution arrangements with United Artists. I found only limited early tie-ins such as a comic adaptation and a boost in novel sales, and no credible evidence of predatory monetization or rushed deceptive release practices.

Well-documented production craft and personnel indicate substantial creative and technical investment.
Film establishes original cinematic Bond canon rather than merely reusing previous screen material.
Contemporary financing and release were negotiated with United Artists under a modest budget, not obviously rushed to market.

View full breakdown

Score factors

Direction	Factor	Evidence	Impact
Against	Production craft	Dr. No employed notable designers and technicians including Ken Adam and credited music by Monty Norman with John Barry arranging the Bond theme, reflecting significant production craft and technical work.[2][3]	-18
Against	Substantive new content	As the first Eon Bond picture the film established cinematic Bond conventions and is a filmed adaptation of Fleming rather than a minimal reuse of existing screen material.[1]	-16
Against	Budget and financing	Contemporary accounts report that Eon and United Artists financed the production at roughly one million dollars and producers worked within tight budgets rather than releasing a low-cost product to extract immediate profit.[1][4]	-12

Confidence: Low · No source-backed commercial-extraction signal was found. · Researched 2026-08-09

Sources reviewed

View 14 more sources

Back to the woke verdict